MARKET

PRAX

PRAX

Praxis Precision Medicines, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

35.35
+1.10
+3.21%
Closed 16:00 11/24 EST
OPEN
34.25
PREV CLOSE
34.25
HIGH
36.10
LOW
34.06
VOLUME
138.31K
TURNOVER
--
52 WEEK HIGH
38.42
52 WEEK LOW
23.90
MARKET CAP
1.30B
P/E (TTM)
-27.1089
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences: * Piper Sandler 32nd Annual Healthcare Conference  Prerecorded fireside chat available on Monday, November 23, 2020 at 10:00 a.m. ET; Institutional investor meetings to be conducted on Tuesday, December 1, 2020 * 3rd Annual Evercore ISI HealthCONx Conference   Fireside chat on Thursday, December 3, 2020 from 3:55 – 4:15 p.m. ETThe events will be available via webcast through the “Events & Presentations” page of the “Investors & Media” section of the company’s website at www.praxismedicines.com. Replays of the webcasts will be available for 90 days following the events.About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis is applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for severe pediatric epilepsies and more broadly for prevalent psychiatric diseases and neurologic disorders. Praxis has established a broad portfolio, including five disclosed programs across multiple central nervous system disorders including, depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates.Investor Contact: Alex Kane Praxis Precision Medicines investors@praxismedicines.com 617-300-8481Media Contact: Ian Stone Canale Communications Ian.stone@canalecomm.com 619-849-5388
GlobeNewswire · 4d ago
Praxis Precision dips 11% as FDA recommended further inspection on PRAX-114 application
Praxis Precision Medicines (PRAX) drops 11% premarket in reaction to receiving comments from the FDA on the full clinical hold of its Investigational New Drug ((IND)) submission for PRAX-114 for the treatment
Seekingalpha · 11/17 13:27
Praxis Precision Medicines Receives FDA Comments On PRAX-114 IND Clinical Hold; Says Expects To Initiate Phase 2/3 Clinical Trial For PRAX-114 In MDD In 1H21
CAMBRIDGE, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central
Benzinga · 11/17 12:47
Praxis Precision Medicines Provides Update On PRAX-114 IND Submission For The Treatment Of Major Depressive Disorder
\- Praxis expects to initiate Phase 2/3 clinical trial for PRAX-114 in MDD in 1H21 -CAMBRIDGE, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that it has received comments from the U.S. Food and Drug Administration (FDA) on the full clinical hold of its Investigational New Drug (IND) submission for PRAX-114 for the treatment of major depressive disorder (MDD). The IND for PRAX-114 was placed on clinical hold by the FDA pending the resolution of certain non-clinical pharmacology and toxicology matters. In its comment letter, the FDA proposed that the Company conduct further toxicological investigation of the effect of PRAX-114 and its metabolites on fertility, reproduction, and embryofetal development to support the planned trial. The Company believes that the results of its ongoing standard fertility and reproductive studies, expected to be completed in the first quarter of 2021, together with the available toxicology package will satisfy the FDA request. The FDA also requested updates to the Investigator’s Brochure and to the requirements for contraception in the protocol.The Company now expects to initiate the randomized, placebo-controlled Phase 2/3 clinical trial for PRAX-114 in MDD in the first half of 2021. The Company is in dialogue with the FDA and intends to explore potential options to accelerate the initiation of the Phase 2/3 clinical trial.About PraxisPraxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis is applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for severe pediatric epilepsies and more broadly for prevalent psychiatric diseases and neurologic disorders. Praxis has established a broad portfolio, including five disclosed programs across multiple central nervous system disorders including, depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates.Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the Company’s expectations regarding the timing in which it will receive additional communications regarding the clinical hold on its IND submission for PRAX-114 from the FDA. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the timing and outcome of the Company’s planned interactions with regulatory authorities, including resolution of the current PRAX-114 clinical hold; the timing and anticipated results of our current preclinical studies and future clinical trials, strategy and future operations; the impact of COVID-19 on countries or regions in which we have operations or do business; the delay of any current preclinical studies or future clinical trials or the development of Praxis’ drug candidates; the risk that the results of current preclinical studies may not be predictive of future results in connection with future clinical trials; Praxis’ ability to successfully demonstrate the safety and efficacy of its drug candidates; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Praxis’ final prospectus related to its initial public offering, dated October 20, 2020, as well as discussions of potential risks, uncertainties, and other important factors in Praxis’ subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Praxis’ views only as of today and should not be relied upon as representing its views as of any subsequent date. Praxis explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.  CONTACT: Investor Contact: Alex Kane investors@praxismedicines.com 617-300-8481 Media Contact: Ian Stone ian.stone@canalecomm.com 619-849-5388
GlobeNewswire · 11/17 12:45
Mid-Afternoon Market Update: Dow Gains 200 Points; GasLog Partners Shares Slide Following Q3 Results
Toward the end of trading Tuesday, the Dow traded up 0.70% to 29,362.83 while the NASDAQ fell 1.14% to 11,579.75. The S&P also fell, dropping 0.16% to 3,544.90
Benzinga · 11/10 19:32
INO, ACB, REV and OGI among midday movers
Gainers: Greenland Technologies (GTEC) +170%.Revlon (REV) +86%.Summit Wireless Technologies (WISA) +50%.Trxade Group (MEDS) +29%.Inovio Pharmaceuticals (INO) +23%.Xperi Holding (XPER) +21%.Pulse Biosciences (PLSE) +21%.Aptevo Therapeutics (APVO) +21%.Boqii Holding (BQ) +20%.StarTek (SRT) +19%.Losers: InnSuites Hospitality
Seekingalpha · 11/10 17:41
Mid-Day Market Update: Nasdaq Tumbles 200 Points; Greenland Technologies Shares Spike Higher
Midway through trading Tuesday, the Dow traded up 0.59% to 29,331.08 while the NASDAQ fell 1.71% to 11,513.19. The S&P also fell, dropping 0.47% to 3,533.70.
Benzinga · 11/10 17:36
Trxade Group, OPKO Health leads healthcare gainers; Arena Pharmaceuticals, Voyager Therapeutics among major losers
Gainers: Trxade Group (MEDS) +35%, OPKO Health (OPK) +19%, Altimmune (ALT) +17%, Sientra (SIEN) +16%, Fulgent Genetics (FLGT) +8%.Losers: Arena Pharmaceuticals (ARNA) -25%, Voyager Therapeutics (VYGR) -21%, Aurora Cannabis (ACB) -21%, OrganiGram Holdings (OGI) -20%, Praxis Precision Medicines (PRAX) -20%.
Seekingalpha · 11/10 16:04
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRAX. Analyze the recent business situations of Praxis Precision Medicines, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRAX stock price target is 53.33 with a high estimate of 65.00 and a low estimate of 40.00.
EPS
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 36.75M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.37%
Pharmaceuticals & Medical Research
0.00%
Key Executives
Chief Executive Officer
Marcio Souza
Co-Founder/Director
Kiran Reddy
Co-Founder
David Goldstein
Chief Financial Officer/Primary Contact
Stuart Chaffee
Chief Scientific Officer
Steven Petrou
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PRAX
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance. Its development stage products include PRAX-114, PRAX-944 and PRAX-562. PRAX-114 is an extrasynaptic-preferring gamma-aminobutyric acid-A (GABAA) receptor positive allosteric modulator (PAM) for the treatment of patients suffering from major depressive disorder (MDD) and perimenopausal depression (PMD). PRAX-944 is a differentiated selective small molecule inhibitor of T-type calcium channel, for the treatment of essential tremor (ET). PRAX-562 is the selective, persistent sodium current blocker in development for the treatment of a range of CNS disorders.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Praxis Precision Medicines Inc stock information, including NASDAQ:PRAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRAX stock methods without spending real money on the virtual paper trading platform.